Cannabis Is Luxembourg's Most Consumed Drug, and the Market Is Evolving

The European Union Drugs Agency (EUDA) released its [1] 2026 European Drug Report this week, and the national data for Luxembourg paints a nuanced picture. Cannabis remains the most commonly consumed drug in the country by a wide margin, with wastewater analysis placing the Grand Duchy among the most exposed countries in Western Europe, behind only the Netherlands. At the same time, fatal overdoses have dropped dramatically, and the drug market itself is shifting in ways that are harder to track.

The EUDA, formerly known as the EMCDDA, monitors drug trends across 29 countries. Its annual report is one of the few sources that lets you compare Luxembourg's situation against its neighbors with consistent methodology. The 2026 edition identifies 50 new psychoactive substances detected for the first time in Europe last year, bringing the total monitored to over 1'050.[2] Among those, synthetic opioids of the nitazene type are drawing particular concern from health authorities.

Luxembourg: High Cannabis, Rising Cocaine

The national data from Luxembourg's EUDA Focal Point tells a story of two trajectories. Cannabis consumption remains high and stable, with wastewater residues placing Luxembourg near the top of the Western European rankings. Cocaine, meanwhile, is on the rise. Cocaine-related treatment requests have nearly doubled since 2013, and seizures rose in 2024 while average purity in 2025 hit a record high. The report's authors note that some of those seizure figures reflect shipments transiting through Luxembourg rather than destined for the domestic market, a consequence of the country's central location and logistics infrastructure at the heart of European drug routes.[3]

The shift from opioids toward cocaine as the dominant substance is a long-term trend, but it is accelerating. An estimated 2'684 high-risk drug users were counted in 2024, up from 2019, even as opioid use continues its long decline.

The Harm Reduction Bright Spot

Here is where Luxembourg stands out. Drug-related deaths fell from 26 in 2000 to 12 in 2024, well below the European average. The country's supervised consumption rooms and harm reduction policies are cited as a benchmark at European level. Since September 2024, a naloxone distribution programme for people leaving prison has added another layer of prevention.[4]

For a country of roughly 660'000 people, 12 overdose deaths a year is a remarkable number, and it is worth asking whether other countries could replicate what Luxembourg has done. The combination of supervised consumption spaces, needle exchange, and now post-release naloxone kits is straightforward in concept but politically difficult in practice in many jurisdictions.

Cannabis Reform: Early Days

Luxembourg's 2023 cannabis reform, which permits home cultivation and private consumption for adults under certain conditions, is still being evaluated. Cannabis-related offences are declining, but the report suggests this reflects changes in the legal framework more than shifts in consumption patterns. Meanwhile, quantities seized and THC levels are rising, a sign that the market is transforming rather than shrinking. The EUDA report also highlights a global trend of illicit cannabis supply routes shifting, with increasing amounts of herbal cannabis trafficked from Canada and the United States into Europe, often concealed in maritime containers or postal traffic.[5]

The contrast between falling offence numbers and rising seizure quantities and potency is a familiar pattern in early-stage drug reform. The law changes what gets counted, not necessarily what gets consumed. It will take several more years of data to see whether Luxembourg's approach is producing genuine public health improvements or simply reclassifying existing behavior.

Why This Matters Beyond Luxembourg

The broader European picture is one of diversification. Fifty new psychoactive substances in a single year means that the drug market is not just growing, it is fragmenting into smaller, faster-moving segments that outpace regulatory responses. Polysubstance use, combining multiple drugs in ways that increase risk, is common and complicates both treatment and policy.

For Luxembourg specifically, the challenge is managing its dual role: a country with strong harm reduction outcomes on one hand, and a logistical crossroads that makes it attractive to traffickers on the other. The 2026 EUDA data suggests that the harm reduction model is working where it counts, keeping people alive, but that the market underneath it is evolving faster than the policy designed to manage it.